 Home > Active Ingredient News > Antitumor Therapy > Clin Cancer Res: The efficacy of niraparib in the treatment of advanced breast cancer with BRCA1/2 germline mutations

Clin Cancer Res: The efficacy of niraparib in the treatment of advanced breast cancer with BRCA1/2 germline mutations

 Last Update: 2021-09-11
 Source: Internet
 Author: User

Tags

2 5 hexanedione

1 4 npt

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

The two proteins encoded by the BRCA1 and BRCA2 genes play a vital role in the DNA damage response, especially in the process of homologous recombination repair (HRR) double-stranded DNA breaks (DSB)
.

Tumors carrying germline mutations of these two genes (gBRCAmut) often have HRR defects and are therefore sensitive to PARP inhibitor treatment

This study aimed to evaluate the activity of the PARP inhibitor Niraparib for advanced breast cancer carrying gBRCAmut
.

Niraparib breast cancer

BRAVO is a randomized, open-label phase 3 trial that recruits advanced breast cancer patients with gBRCAmut, HER2-negative, ≤2 previous treatments or recurrence 12 months after adjuvant chemotherapy, and randomized 2:1 to Nira Parli group (n=141) or chemotherapy group (PC; eribulin, capecitabine, vinorelbine or gemcitabine monotherapy, n=74)
.

The enrolled hormone receptor-positive patients have received ≥1 line of endocrine therapy and progressed during metastatic therapy or relapsed within 12 months after (new) adjuvant therapy

In the interim and final analysis, the PFS of the two groups

After the scheduled interim analysis, recruitment was stopped due to ineffectiveness
.

There is a high degree of inconsistency between the PC group’s local and the PFS assessed by the center, leading to information review

In the final analysis (median follow-up was 19.

OS of two groups

The median OS in the Nirapali group and PC group was 14.
5 months vs 15.
2 months (HR 0.
95, 95%CI 0.
63-1.
42, p=0.
79)
.

The objective response rates of the two groups were 35% (95% CI 26-45) and 31% (95% CI 19-46), respectively

The median OS of the Nirapali group and the PC group was 14.

Original source:

Nicholas C.

Niraparib for Advanced Breast Cancer with Germline BRCA1 and BRCA2 Mutations: the EORTC 1307-BCG / BIG5-13 / TESARO PR-30-50-10-C BRAVO Study in this message

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.